Limitations and Unmet Needs of Existing Standard Treatments

The existing bipolar disorder treatment market has relied on mood stabilizers such as lithium and combination therapies with atypical antipsychotics. However, more than half of the patients discontinue treatment or are dissatisfied due to drug side effects such as weight gain, sexual dysfunction, and metabolic complications. In particular, patients with atypical depression, which is accompanied by increased appetite and anhedonia, have faced the paradox of their symptoms worsening with existing drugs. To address this unmet medical need, there is an urgent need for the development of new drugs that precisely target the central nervous system (CNS).

Successful Phase 2 Clinical Trial of Autobahn's Elunetiro and its Differentiated Mechanism

Autobahn Therapeutics, a U.S.-based company, is developing elunetiro, a brain-targeted thyroid hormone receptor beta (TRβ) agonist, which presents a unique mechanism. Unlike existing antidepressants that regulate serotonin or dopamine, this substance promotes energy metabolism in brain nerve cells and induces neuroplasticity, thereby restoring brain function itself. An analysis of 21 patients who participated in the Phase 2 clinical trial showed that 75% of the patients had a treatment response rate and 50% had a remission rate within 6 weeks of administration, and the Hamilton Depression Rating Scale (HAMD-17) score was improved by 16.8 points. It has demonstrated rapid efficacy within two weeks while minimizing side effects and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Pursuit of New Drugs Targeting the Glutamate Pathway

Pipelines targeting the glutamate transmission system are also attracting attention for the treatment of bipolar depression and mania. Syremis Therapeutics, an Israeli company, is developing ST-901, an NMDA receptor antagonist, in the non-clinical (IND-enabling) stage with $165 million in funding. In addition, Rapport Therapeutics is conducting a Phase 2 clinical trial of RAP-219, which targets TARPγ8, an AMPA receptor modulator auxiliary protein that acts only on specific areas of the brain. These signaling modulators demonstrate the potential of precision psychiatry by eliminating systemic side effects caused by existing treatments.

Alto Bio's Attempt to Enhance Neuroplasticity and Market Prospects

ALTO-100, developed by Alto Neuroscience, is a new oral small molecule therapeutic that enhances neuroplasticity in the hippocampus, the cognitive and emotional regulation area of the brain. It is currently conducting a Phase 2b clinical trial in patients with bipolar depression, combined with standard treatments, and is scheduled to announce the topline results within this year. With various new drugs with diversified brain science mechanisms expected to announce clinical data in the second half of this year, investor expectations are high. The global bipolar disorder treatment market, estimated at $5.2 billion to $9.2 billion, is expected to undergo significant structural changes with the advent of next-generation treatments.